Immunotherapy is emerging as a promising option to improve outcomes in patients with NSCLC, including agents that target programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) (6). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.